Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXAS Exact Sciences	$50.46 -3.4%	$54.35	$39.97 ▼ $72.83	$9.53B	0.95	2.57 million shs	1.29 million shs
HALO Halozyme Therapeutics	$56.63 -2.0%	$54.48	$42.01 ▼ $70.51	$6.98B	1.15	1.75 million shs	558,115 shs
LGND Ligand Pharmaceuticals	$138.87 +0.9%	$111.41	$90.29 ▼ $139.53	$2.68B	0.84	118,801 shs	205,687 shs
RGEN Repligen	$116.76 -5.9%	$124.79	$102.97 ▼ $182.52	$6.58B	1.11	727,013 shs	691,104 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXAS Exact Sciences	-2.72%	-2.08%	-0.63%	+25.57%	+5.75%
HALO Halozyme Therapeutics	-0.34%	+0.31%	+8.85%	-1.67%	+5.59%
LGND Ligand Pharmaceuticals	+6.13%	+10.07%	+22.24%	+31.06%	+36.11%
RGEN Repligen	+3.58%	-7.43%	+2.50%	-4.58%	-6.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EXAS Exact Sciences	4.6942 of 5 stars	3.5	5.0	4.7	2.7	2.5	0.6
HALO Halozyme Therapeutics	4.9625 of 5 stars	3.1	4.0	4.4	2.9	2.5	4.4
LGND Ligand Pharmaceuticals	3.5289 of 5 stars	1.5	1.0	4.4	2.1	3.3	1.9
RGEN Repligen	4.7212 of 5 stars	4.3	1.0	4.5	3.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXAS Exact Sciences	2.95	Moderate Buy	$70.50	39.73% Upside
HALO Halozyme Therapeutics	2.17	Hold	$62.70	10.72% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	5.98% Upside
RGEN Repligen	2.69	Moderate Buy	$170.75	46.25% Upside

Current Analyst Ratings Breakdown

Latest LGND, EXAS, RGEN, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$58.00 ➝ $60.00
7/10/2025	HALO Halozyme Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$55.00
7/8/2025	EXAS Exact Sciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00
7/8/2025	RGEN Repligen	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$140.00 ➝ $130.00
6/24/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $65.00
6/24/2025	RGEN Repligen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$150.00
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/14/2025	HALO Halozyme Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $62.00
5/13/2025	HALO Halozyme Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/13/2025	HALO Halozyme Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform	$47.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXAS Exact Sciences	$2.76B	3.45	$5.29 per share	9.53	$12.98 per share	3.89
HALO Halozyme Therapeutics	$1.02B	6.87	$4.54 per share	12.47	$2.86 per share	19.80
LGND Ligand Pharmaceuticals	$167.13M	16.03	$1.72 per share	80.67	$43.95 per share	3.16
RGEN Repligen	$634.44M	10.34	$3.03 per share	38.54	$35.21 per share	3.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXAS Exact Sciences	-$1.03B	-$5.51	N/A	100.91	11.46	-36.06%	-3.75%	-1.68%	8/6/2025 (Estimated)
HALO Halozyme Therapeutics	$444.09M	$3.76	15.06	9.10	0.39	44.76%	136.91%	26.05%	8/5/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	37.43	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)
RGEN Repligen	-$25.51M	-$0.45	N/A	49.47	3.43	-3.93%	4.53%	3.17%	7/29/2025 (Estimated)

Latest LGND, EXAS, RGEN, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EXAS Exact Sciences	-$0.04	N/A	N/A	N/A	$774.43 million	N/A
8/5/2025	Q2 2025	HALO Halozyme Therapeutics	$1.22	N/A	N/A	N/A	$282.66 million	N/A
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
7/29/2025	Q2 2025	RGEN Repligen	$0.40	N/A	N/A	N/A	$174.62 million	N/A
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million
5/1/2025	Q1 2025	EXAS Exact Sciences	-$0.37	-$0.21	+$0.16	-$0.54	$688.58 million	$706.79 million
4/29/2025	Q1 2025	RGEN Repligen	$0.35	$0.39	+$0.04	$0.10	$163.65 million	$169.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGEN Repligen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXAS Exact Sciences	0.97	2.73	2.38
HALO Halozyme Therapeutics	3.13	8.39	7.30
LGND Ligand Pharmaceuticals	N/A	5.27	5.02
RGEN Repligen	0.27	6.79	5.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXAS Exact Sciences	88.82%
HALO Halozyme Therapeutics	97.79%
LGND Ligand Pharmaceuticals	91.28%
RGEN Repligen	97.64%

Insider Ownership

Company	Insider Ownership
EXAS Exact Sciences	1.20%
HALO Halozyme Therapeutics	2.40%
LGND Ligand Pharmaceuticals	7.00%
RGEN Repligen	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXAS Exact Sciences	7,000	188.64 million	186.37 million	Optionable
HALO Halozyme Therapeutics	390	123.22 million	120.26 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable
RGEN Repligen	1,778	56.18 million	55.51 million	Optionable

LGND, EXAS, RGEN, and HALO Headlines

Recent News About These Companies

Repligen Corp (RGEN) Trading Down 4.19% on Jul 18

2 hours ago | gurufocus.com

Q1 Earnings Estimate for Repligen Issued By Leerink Partnrs

5 hours ago | marketbeat.com

Repligen to Report Second Quarter 2025 Financial Results

July 17 at 7:30 AM | globenewswire.com

Segall Bryant & Hamill LLC Grows Stake in Repligen Corporation (NASDAQ:RGEN)

July 17 at 6:51 AM | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Shares Acquired by Rice Hall James & Associates LLC

July 15 at 5:45 AM | marketbeat.com

Repligen (NASDAQ:RGEN) Trading Down 5.4% - Here's Why

July 14, 2025 | marketbeat.com

TimesSquare Capital Management LLC Has $30.03 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)

July 14, 2025 | marketbeat.com

Slow Capital Inc. Has $4.18 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)

July 14, 2025 | marketbeat.com

New York State Common Retirement Fund Grows Holdings in Repligen Corporation (NASDAQ:RGEN)

July 14, 2025 | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Shares Bought by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

Teacher Retirement System of Texas Increases Stake in Repligen Corporation (NASDAQ:RGEN)

July 11, 2025 | marketbeat.com

Banque Pictet & Cie SA Has $3.12 Million Stock Position in Repligen Corporation (NASDAQ:RGEN)

July 10, 2025 | marketbeat.com

Principal Financial Group Inc. Increases Position in Repligen Corporation (NASDAQ:RGEN)

July 9, 2025 | marketbeat.com

Repligen And 2 Other Stocks That May Be Trading Below Estimated Value

July 8, 2025 | finance.yahoo.com

Evercore ISI Cuts Repligen (NASDAQ:RGEN) Price Target to $130.00

July 8, 2025 | marketbeat.com

New York State Teachers Retirement System Has $6.49 Million Holdings in Repligen Corporation (NASDAQ:RGEN)

July 6, 2025 | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Shares Sold by Impax Asset Management Group plc

July 5, 2025 | marketbeat.com

1 Healthcare Stock to Target This Week and 2 to Be Wary Of

July 3, 2025 | msn.com

WCM Investment Management LLC Has $13.74 Million Stock Position in Repligen Corporation (NASDAQ:RGEN)

July 3, 2025 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Has $3.98 Million Stake in Repligen Corporation (NASDAQ:RGEN)

July 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Blockchain Stocks to Profit in a Decentralized World
By Chris Markoch | June 24, 2025
View 3 Blockchain Stocks to Profit in a Decentralized World
Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
By Leo Miller | June 25, 2025
View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
How Texas Roadhouse Is Winning in a Changing Consumer Market
By Dan Schmidt | July 14, 2025
View How Texas Roadhouse Is Winning in a Changing Consumer Market
Texas Instruments Stock: Congress Likes It, Should You Too?
By Thomas Hughes | June 24, 2025
View Texas Instruments Stock: Congress Likes It, Should You Too?

LGND, EXAS, RGEN, and HALO Company Descriptions

Exact Sciences NASDAQ:EXAS

$50.46 -1.76 (-3.36%)

As of 03:34 PM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Halozyme Therapeutics NASDAQ:HALO

$56.63 -1.18 (-2.05%)

As of 03:34 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Ligand Pharmaceuticals NASDAQ:LGND

$138.86 +1.30 (+0.94%)

As of 03:33 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Repligen NASDAQ:RGEN

$116.76 -7.29 (-5.87%)

As of 03:34 PM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time